Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Publication Date timeline is not available.
Page 1
Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients.
HIV Clin Trials. 2014 Sep-Oct;15(5):199-208. doi: 10.1310/hct1505-199.
HIV Clin Trials. 2014.
PMID: 25350958
Prevalent polymorphisms in wild-type HIV-1 integrase are unlikely to engender drug resistance to dolutegravir (S/GSK1349572).
Vavro C, Hasan S, Madsen H, Horton J, DeAnda F, Martin-Carpenter L, Sato A, Cuffe R, Chen S, Underwood M, Nichols G.
Vavro C, et al. Among authors: martin carpenter l.
Antimicrob Agents Chemother. 2013 Mar;57(3):1379-84. doi: 10.1128/AAC.01791-12. Epub 2013 Jan 7.
Antimicrob Agents Chemother. 2013.
PMID: 23295935
Free PMC article.
Item in Clipboard
Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks.
Quercia R, Roberts J, Martin-Carpenter L, Zala C.
Quercia R, et al. Among authors: martin carpenter l.
Clin Drug Investig. 2015 Mar;35(3):211-9. doi: 10.1007/s40261-014-0266-2.
Clin Drug Investig. 2015.
PMID: 25637061
Free PMC article.
Item in Clipboard
Cite
Cite
ARTICLE TYPE
ARTICLE LANGUAGE
AGE
Filters on the sidebar will be reset to the default list and any currently applied filters will be cleared.